Join MitoAction and Dr. Jan Smeitink, CEO of Khondrion for our our March Expert Series presentation. MELAS spectrum (m.3243A>G) disorders belong to the most frequently encountered group of primary mitochondrial diseases with an unmet medical need for treatment development. Following an introduction of the clinical disease spectrum Dr. Smeitink will discuss the development and state-of-art of Khondrion’s lead product sonlicromanol.
Having a better understanding of what things are associated with LCHADD retinopathy can provide insight towards developing treatment. During this presentation, Dr. Gillingham will...
Friday, July 24Auditorium – 1:10pm – INFORM & FAOD Community Update About the Speaker: Cleveland Family Endowed Pediatric Research, School of MedicineProfessor of Human...
MitoAction Interview with Stephen